Reaction
Kl-6 Increased reporting signals
As of the last recalculation, Kl-6 Increased appears in 211 FAERS reports alongside 4 co-occurring drug terms. The strongest observed disproportionality signal is FAM-TRASTUZUMAB DERUXTECAN-NXKI (PRR 113.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Fam-Trastuzumab Deruxtecan-Nxki | 11 | 113.5 | 113.6 |
| Nintedanib | 25 | 89.1 | 89.1 |
| Pembrolizumab | 46 | 54.9 | 54.9 |
| Lenvatinib | 10 | 31.5 | 31.5 |